Cash on Hand for AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's latest reported cash and short-term investments is $5.74B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AZN
Currently viewingRevenueSwitch metric
Latest period
$5.74B
YoY change
+3.9%
5Y CAGR
-6.4%
Peak year (2010)
$12.55B
Latest annual
$5.74B
Cash on Hand history chart for AstraZeneca (AZN) from 1990 to 2025
Cash on Hand history table for AstraZeneca (AZN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $5.74B | +3.9% | ||
| 2024 | $5.53B | -5.7% | ||
| 2023 | $5.86B | -6.1% | ||
| 2022 | $6.24B | -2.4% | ||
| 2021 | $6.40B | -19.9% | ||
| 2020 | $7.99B | +28.6% | ||
| 2019 | $6.22B | +9.5% | ||
| 2018 | $5.68B | +24.7% | ||
| 2017 | $4.55B | -22.8% | ||
| 2016 | $5.90B | -13.9% | ||
| 2015 | $6.85B | -4.2% | ||
| 2014 | $7.16B | -28.5% | ||
| 2013 | $10.01B | +17.5% | ||
| 2012 | $8.52B | -27.9% | ||
| 2011 | $11.82B | -5.8% | ||
| 2010 | $12.55B | +9.8% | ||
| 2009 | $11.43B | +160.2% | ||
| 2008 | $4.39B | -27.3% | ||
| 2007 | $6.04B | -22.1% | ||
| 2006 | $7.76B | +17.5% | ||
| 2005 | $6.60B | +25.4% | ||
| 2004 | $5.26B | +33.3% | ||
| 2003 | $3.95B | -15.7% | ||
| 2002 | $4.69B | -14.2% | ||
| 2001 | $5.46B | +22.7% | ||
| 2000 | $4.45B | +35.5% | ||
| 1999 | $3.29B | +433.7% | ||
| 1998 | $615.82M | -48.9% | ||
| 1997 | $1.21B | -27.8% | ||
| 1996 | $1.67B | +36.4% | ||
| 1995 | $1.22B | +6.5% | ||
| 1994 | $1.15B | -25.9% | ||
| 1993 | $1.55B | +144.8% | ||
| 1992 | $633.98M | -2.9% | ||
| 1991 | $653.04M | +6.5% | ||
| 1990 | $613.40M | — |
Cash on Hand values are taken from AstraZeneca's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, AstraZeneca (AZN) reported cash and short-term investments of $5.74B – edged up 3.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca cash and short-term investments compounded at -6.4% per year, with a net decline across the window.
AstraZeneca cash and short-term investments peaked at $12.55B in 2010; the latest annual figure is $5.74B in 2025 (54.3% below peak).
Across the available history, cash and short-term investments reached its high of $12.55B in 2010 and its low of $613.40M in 1990.
AstraZeneca (AZN) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $12.34B.
AstraZeneca Cash on Hand by Year
AstraZeneca Cash on Hand 2025: $5.74B
AstraZeneca cash and short-term investments in 2025 was $5.74B, edged up 3.9% from 2024.
AstraZeneca Cash on Hand 2024: $5.53B
AstraZeneca cash and short-term investments in 2024 was $5.53B, declined 5.7% below 2023.
AstraZeneca Cash on Hand 2023: $5.86B
AstraZeneca cash and short-term investments in 2023 was $5.86B, declined 6.1% below 2022.
AstraZeneca Cash on Hand 2022: $6.24B
AstraZeneca cash and short-term investments in 2022 was $6.24B, edged down 2.4% below 2021.
AstraZeneca Cash on Hand 2021: $6.40B
AstraZeneca cash and short-term investments in 2021 was $6.40B.
See more financial history for AstraZeneca (AZN).
Sector peers — Cash on Hand
Companies in the same sector as AstraZeneca, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $10.11B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is AstraZeneca's cash and short-term investments?
- Latest reported cash and short-term investments for AstraZeneca (AZN) is $5.74B (period ending December 31, 2025).
How has AstraZeneca cash and short-term investments changed year-over-year?
- AstraZeneca (AZN) cash and short-term investments changed +3.9% year-over-year on the latest annual filing.
What is the long-term growth rate of AstraZeneca cash and short-term investments?
- AstraZeneca (AZN) cash and short-term investments compound annual growth rate is -6.4% over the most recent 5 years available.
When did AstraZeneca cash and short-term investments hit its highest annual value?
- AstraZeneca cash and short-term investments reached its highest annual value of $12.55B in 2010.
What was AstraZeneca cash and short-term investments in 2024?
- AstraZeneca (AZN) cash and short-term investments in 2024 was $5.53B.
What was AstraZeneca cash and short-term investments in 2025?
- AstraZeneca (AZN) cash and short-term investments in 2025 was $5.74B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
AZN Overview
Company profile, financial tools, and key metrics
AZN Revenue Counter
Earns $1,863 every second. See per minute, hour, and day.
AZN Earnings Counter
Earns $324.23 per second net profit. See per minute, hour, and day.
AZN Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
AZN What If Invested
What if you had invested $1,000? See historical returns from any date.
AZN How It Makes Money
Discover visual breakdown of $58.74B in revenue — where it comes from and where it goes.
AZN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AZN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AZN Daily Price Character
Steady · 49.4% historical win rate (green days). Streaks & record days.
AZN Buybacks
0.16% TTM buyback yield. Shareholder yield & SBC comparison.
AZN Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
AZN Dividend Profile
Yield: 1.73%. Safety: 6/8. See full history.
AZN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AZN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.